IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: David P. BINGAMAN, et al.

Serial No: 10/771,829 (Conf. #3961)

Filed: 4 February 2004

Examiner:

Group Art Unit: 1614

FOR: USE OF STEROIDS TO TREAT PERSONS SUFFERING FROM OCULAR

DISORDERS

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. 1.56, 1.97, AND 1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. 1.56, 1.97, and 1.98, Applicants submit the patents, articles, and other information referenced in the specification as filed. The references are listed on the attached PTO Form 1449. Applicants are submitting a copy of the non-patent literature in accordance with 37 CFR 1.98(a)(2), copies of the U.S. patents are not enclosed.

Applicants request that the listed patents, articles, and other information be considered during prosecution of this application and that they appear among the "References Cited" on any patent issuing herefrom.

Respectfully submitted,

Γefesa J. S**ć**hultz

,

Registration No. 40,256

(817) 551-4231

Address for Correspondence: Alcon Research, Ltd. Attn: Teresa J. Schultz 6201 S. Freeway, Mail Code Q-148 Fort Worth, TX 76134-2099

Attorney Docket No.: 2462 US



PTO/SB/08A (04-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known			
Application Number	USSN 10/771,829 (Conf #3961)		
Filing Date	4 February 2004		
First Named Inventor	David P. BINGAMAN, et al.		
Art Unit	1614		
Examiner Name			
Attorney Docket Number	2462 110		

Eugariana	1 6:45		U. S. PATENT D		
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ^{2 (# known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevan Figures Appear
	A1	^{US-} 4,853,224	08/01/1989	Wong	
	A2	^{US-} 5,164,188	11/17/1992	Wong	
	A3	^{US-} 5,378,475	01/03/1995	Smith et al.	
	A4	^{US-} 5,773,019	06/30/1998	Ashton et al.	
	A5	^{US-} 5,869,079	02/09/1999	Wong et al.	
	A6	^{US-} 6,120,789	09/19/2000	Dunn	
	A7	^{US-} 6,413,245	07/02/2002	Yaacobi et al.	
	A8	^{US-} 6,413,540	07/02/2002	Yaacobi	
	A9	^{US-} 6,416,777	07/09/2002	Yaacobi	
	A10	US-			
	A11	US-			
	A12	US-			
	A13	US-			
	A14	US-			
	A15	US-			
	A16	US-			
	A17	US-			
	A18	US-			
	A19	US-			

<u> </u>	FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ "Number ⁴ "Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	Τ ⁶
	A20					
	A21				-	
	A22				7	
	A23					
	A24				-	
	A25					\sqcap

Examiner	Date	
Signature	Considered	
J. g	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Include the communication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Traisation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (04-03)
Approved for use through 04/30/2003. OMB 0651-0031

Substitute for form 1449/PTO				e required to respond to a collection of information unless it contains a valid OMB control number Complete if Known		
				Application Number	USSN 10/771,829 (Conf #3961)	
INFORMATION DISCLOSURE				Filing Date	4 February 2004	
STATEMENT BY APPLICANT		First Named Inventor	David P. BINGAMAN, et al.			
(Use as many sheets as necessary)			anne and	Art Unit	1614	
(Ose as many sneets as necessary)		Examiner Name				
Sheet	2	of	2	Attorney Docket Number	2462 US	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	B1	Penn, et al., "The Effect of an Angiostatic Steroid on Neovascularization in a Rat Model of Retinopathy of Prematurity", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 42(1):283-290, January 2001	
	B2		
	В3		
	B4		
	B5		
	В6		
	В7		
	В8		
	В9		
	B10		

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.